Branded generic and healthcare major Abbott India Limited announced its financial results for the second quarter ended 30 September 2026, delivering a resilient performance driven by steady domestic pharmaceutical demand, cost discipline, and robust growth in its core therapeutic portfolios.

For the July–September quarter, the company reported an Operating EBITDA of Rs. 568 crore, marking a double-digit rise compared to the Rs. 502 crore recorded in the corresponding quarter of the previous financial year. This operational growth was complemented by enhanced efficiency, allowing the company’s operating EBITDA margins to expand by 53 basis points to 29.11%, up from 28.58% year-on-year (YoY).

The pharmaceutical leader crossed a significant milestone as its quarterly revenue from operations grew 11.03% YoY, surpassing the Rs. 1,951 crore mark for the first time to touch Rs. 1,951.01 crore. This is an increase of Rs. 193.86 crore over the Rs. 1,757.15 crore registered in the same period last year. Meanwhile, total revenue for the quarter stood at Rs. 2,019.07 crore.

Abbott India's bottom line tracked a similar upward trajectory, with net profit (Profit After Tax) rising 9.19% YoY to Rs. 453.45 crore, compared to Rs. 415.27 crore in the prior-year period. Growth was well-supported by robust performance in established brands alongside strategic product launches.

For the cumulative six-month period ending 30 September 2026, the healthcare giant maintained its steady momentum. It reported total sales of Rs. 3,764.69 crore and a net income of Rs. 8,819.70 crore, highlighting long-term structural strength in the domestic formulation market.